These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28729401)

  • 1. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.
    Shien K; Papadimitrakopoulou VA; Ruder D; Behrens C; Shen L; Kalhor N; Song J; Lee JJ; Wang J; Tang X; Herbst RS; Toyooka S; Girard L; Minna JD; Kurie JM; Wistuba II; Izzo JG
    Mol Cancer Ther; 2017 Oct; 16(10):2234-2245. PubMed ID: 28729401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway.
    Chen X; Yang W; Deng X; Ye S; Xiao W
    Mol Vis; 2020; 26():517-529. PubMed ID: 32818015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
    Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
    Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of
    Zhang P; Li Z; Yang G
    Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34713300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
    Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
    Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.
    Smigiel JM; Parameswaran N; Jackson MW
    Mol Cancer Res; 2017 Apr; 15(4):478-488. PubMed ID: 28053127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
    Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
    Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
    Song L; Rawal B; Nemeth JA; Haura EB
    Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
    Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
    Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
    Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
    J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition.
    Guo L; Chen C; Shi M; Wang F; Chen X; Diao D; Hu M; Yu M; Qian L; Guo N
    Oncogene; 2013 Nov; 32(45):5272-82. PubMed ID: 23318420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells.
    Yang Y; Wang W; Chang H; Han Z; Yu X; Zhang T
    J Cell Mol Med; 2019 Nov; 23(11):7331-7341. PubMed ID: 31507089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPN3 plays oncogenic role in non-small cell lung cancer by activating the JAK1/2-STAT3 pathway.
    Meng J; Zhang C; Zhu N; Zhang C; Liu M; Han Z; Li Y
    Environ Toxicol; 2023 Aug; 38(8):1968-1979. PubMed ID: 37186036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.
    Bryson BL; Junk DJ; Cipriano R; Jackson MW
    Cell Cycle; 2017 Feb; 16(4):319-334. PubMed ID: 27892764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.
    Fossey SL; Bear MD; Kisseberth WC; Pennell M; London CA
    BMC Cancer; 2011 Apr; 11():125. PubMed ID: 21481226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.
    Goulet CR; Champagne A; Bernard G; Vandal D; Chabaud S; Pouliot F; Bolduc S
    BMC Cancer; 2019 Feb; 19(1):137. PubMed ID: 30744595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition.
    Yang X; Gao Y; Liu Q; Wan L; Liu H; Bian W; Du Y; Huang C
    Oncol Rep; 2021 Feb; 45(2):459-468. PubMed ID: 33416163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
    Chen D; Chu CY; Chen CY; Yang HC; Chiang YY; Lin TY; Chiang IP; Chuang DY; Yu CC; Chow KC
    J Pathol; 2008 Jul; 215(3):290-9. PubMed ID: 18491353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.